BIIB 059

Drug Profile

BIIB 059

Alternative Names: BIIB-059

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Monoclonal antibodies
  • Mechanism of Action C-type lectin modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous lupus erythematosus; Systemic lupus erythematosus

Most Recent Events

  • 26 Sep 2017 Biogen initiates enrolment in a phase I trial in Healthy volunteers in USA (SC) (NCT03224793)
  • 24 Jul 2017 Biogen plans a phase I trial in Healthy volunteers (SC) (NCT03224793)
  • 14 Jun 2017 Pharmacodynamics and adverse events data from a phase I trial in Systemic lupus erythematosus 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top